Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of pozelimab in patients with CHAPLE disease / protein-losing enteropathy due to CD55 deficiency
MOH_2020-04-27_007335Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pozelimab in CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy, sponsored by Regeneron Pharmaceuticals. Started Nov 2019; status: completed.
02
Drugs
pozelimab
03
Conditions
CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy
Beyond the preview
Go deeper on MOH_2020-04-27_007335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-27_007335.